Chest pain screening for hidden cardiac amyloidosis
CHEST-CA: Study of Chest Pain and Hidden Cardiac Amyloidosis
We will test whether men over 65 who have chest pain but no coronary artery disease might have hidden cardiac amyloidosis using blood and urine tests, ECG and echocardiography, bone scintigraphy, and sometimes a heart biopsy.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 300 (estimated) |
| Ages | 65 Years and up |
| Sex | Male |
| Sponsor | Rigshospitalet, Denmark Academic / other |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT07435168 on ClinicalTrials.gov |
What this trial studies
This is a prospective observational study enrolling men older than 65 who present with chest pain but have no evidence of coronary artery disease on CT coronary angiography or Rb-PET. Participants will undergo blood and urine sampling, ECG, transthoracic echocardiography, and bone scintigraphy to look for signs of cardiac amyloid, with endomyocardial biopsy reserved for inconclusive cases. The primary aim is to determine the prevalence of cardiac amyloidosis in this defined chest-pain population. Data collected at Rigshospitalet will inform whether routine screening in similar patients is warranted.
Who should consider this trial
Good fit: Men over 65 with chest pain who have had a CT coronary angiogram or Rb-PET showing no coronary artery disease and who do not have a prior history of amyloidosis.
Not a fit: Patients who are female, younger than 65, have confirmed coronary artery disease on imaging, or already have a diagnosis of amyloidosis are unlikely to benefit from this screening-focused study.
Why it matters
Potential benefit: If successful, the study could identify men with previously unrecognized cardiac amyloidosis earlier, enabling earlier management and appropriate follow-up.
How similar studies have performed: Noninvasive bone scintigraphy for transthyretin cardiac amyloidosis has been validated and prevalence studies in older adults with heart failure or aortic stenosis have shown notable rates, but applying this approach specifically to chest-pain patients without CAD is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: No signs of CAD through Rb-PET and/or CT coronary arteriogram Exclusion Criteria: Previous history of amyloidosis
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Study coordinator: Navid Noory, MD
- Email: navid.noory@regionh.dk
- Phone: 4535453108
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.